Fig. 2From: Immunological repertoire linked to PSTPIP1-associated myeloid-related inflammatory (PAMI) syndromeFour-year follow-up of laboratory parameters in the index patient, including response to anti-IL1B therapy. Systemic inflammation associated with marked hematological involvement is observed, with high levels of C-reactive protein (CRP), anemia, neutropenia and thrombocytopenia. Dashed lines indicate the onset of anti-IL1B (canakinumab)Back to article page